Feb 23 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* RECEIVES U.S. FDA ORPHAN DESIGNATION FOR DRUG FOR TREATMENT OF FORM OF PRIMARY BRAIN CANCER
Feb 23 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* RECEIVES U.S. FDA ORPHAN DESIGNATION FOR DRUG FOR TREATMENT OF FORM OF PRIMARY BRAIN CANCER